Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer

References

• Van Cutsem E, Nordlinger B, Cervantes A, ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical practice guidelines for treatment. Ann. Oncol. 21(Suppl. 5), v93–v97 (2010).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9, 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. 23, 3697–3705 (2005).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013–2019 (2008).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26, 5326–5334 (2009).
   Web of Science ®Google Scholar
• Kozloff M, Ulcickas Yood M, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. Oncologist. 14, 862–870 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20, 1842–1847 (2009).
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5), 487–494 (2011).
   PubMed Web of Science ®Google Scholar
• Yao SK, Ober JC, Krishnaswami A et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 86, 1302–1309 (1992).
   PubMed Web of Science ®Google Scholar
• De Graaf JC, Banga JD, Moncada S, Palmer RM, De Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 85, 2284–2290 (1992).
   PubMed Web of Science ®Google Scholar
• Feihl F, Liaudet L, Waeber B, Levy BI. Hypertension: a disease of the microcirculation? Hypertension 48, 1012–1017 (2006).
   PubMed Web of Science ®Google Scholar
• Mourad JJ, des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann. Oncol. 19, 927–934 (2008).
   PubMed Web of Science ®Google Scholar
• Ciuffetti G, Schillaci G, Innocente S et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J. Hypertens. 21, 2297–2303 (2003).
   PubMed Web of Science ®Google Scholar
• Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am. J. Hypertens. 23, 460–468 (2010).
   PubMed Web of Science ®Google Scholar
• Maitland ML, Moshier K, Imperial J et al. Blood pressure as a biomarker for sorafenib, an inhibitor of VEGF signalling pathway. J. Clin. Oncol. 24(Suppl. 20), Abstract 2035 (2006).
   PubMedGoogle Scholar
• Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann. Oncol. 20, 227–230 (2009).
   PubMed Web of Science ®Google Scholar
• De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother. Pharmacol. 68, 1207–1213 (2011).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Douglas PS, Middleton JP et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). Presented at: 46th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 4–8 June 2010.
   Google Scholar
• Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707–716 (2003).
   PubMed Web of Science ®Google Scholar
• Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129–1136 (2008).
   PubMed Web of Science ®Google Scholar
• Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 3, 27–34 (2002).
   PubMed Web of Science ®Google Scholar
• Tam BY, Wei K, Rudge JS et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat. Med. 12, 793–800 (2006).
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99, 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncologica. 49, 287–297 (2010).
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu, D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300, 2277–2285 (2008).
   PubMed Web of Science ®Google Scholar
• Hang XF, Xu WS, Wang JX et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur. J. Clin. Pharmacol. 67, 613–623 (2011).
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O'Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11–16 (2011).
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 91, 173–180 (2005).
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Presented at: 42th Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, 2–6 June 2006.
   Google Scholar
• Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 10, 559–568 (2009).
   PubMed Web of Science ®Google Scholar
• Cella DF. Measuring quality of life in palliative care. Semin. Oncol. 22, 73–81 (1995).
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Wallace JF, Holmgren E et al. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist 13, 1021–1029 (2008).
   PubMed Web of Science ®Google Scholar
• Ward PR, Liem AKD, Wang EJ et al. Physical function and quality of life in frail and/or elderly metastatic colorectal cancer patients treated with bevacizumab and capecitabine: an exploratory analysis. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2012.
   Google Scholar
• Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van Cutsem E, Díaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25, 5225–5232 (2007).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28, 4697–4705 (2010).
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 4706–4713 (2010).
   PubMed Web of Science ®Google Scholar
• Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J. Invest. Dermatol. 109, 751–756 (1997).
   PubMed Web of Science ®Google Scholar
• Woodworth CD, Michael E, Marker D et al. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol. Cancer Ther. 4, 650–658 (2005).
   PubMed Web of Science ®Google Scholar
• Pomerantz RG, Mirvish ED, Geskin LJ. Cutaneous reactions to epidermal growth factor receptor inhibitors. J. Drugs Dermatol. 9, 1229–1234 (2010).
   PubMed Web of Science ®Google Scholar
• Balagula Y, Wu S, Su X, Lacouture ME. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Ann. Oncol. 22, 2366–2374 (2011).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Kim E S, Eaby B et al. Epidermal growth factor receptor inhibitor associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 12, 610–621 (2007).
   PubMed Web of Science ®Google Scholar
• Scope A, Agero ALC, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab associated acne-like eruption. J. Clin. Oncol. 25, 5390–5396 (2007).
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Mitchell EP, Piperdi B et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 1351–1357 (2010).
   PubMed Web of Science ®Google Scholar
• Saltz L, Kies M, Abbruzzese JL et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Presented at: 39th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 31 May–3 June 2003.
   Google Scholar
• Saltz L, Rubin MS, Hochster H, et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Presented at: AACR 92nd Annual Meeting. New Orleans, LA, USA, 24–28 March 2001.
   Google Scholar
• Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Presented at: 37th Annual Meeting of the American Society of Clinical Oncology. San Francisco, CA, USA, 12–15 May 2001.
   Google Scholar
• Lievre A, Bachet JB, Bioge V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-?-1,3-galactose. N. Engl. J. Med. 358, 1109–1117 (2008).
   PubMed Web of Science ®Google Scholar
• Fakih M. Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology 22, 74–76 (2008).
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Galluzzo S, Santini D, et al. Eary magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann. Oncol. 22, 1141–1146 (2011).
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 2311–2319 (2008).
   PubMed Web of Science ®Google Scholar
• Au HJ, Karapetis CS, O'Callaghan CJ et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J. Clin. Oncol. 27, 1822–1828 (2009).
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367, 1596–1606 (2012).
   PubMed Web of Science ®Google Scholar